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Measurement of pharmacokinetic parameters in histologically graded 
invasive breast tumours using dynamic contrast enhanced MRI
Abstract
Dynamic contrast enhanced MRI (DCE-MRI) has demonstrated high sensitivity for detection of breast 
cancer. Analysis of correlation between quantitative DCE-MRI findings and prognostic factors (such 
as histological tumour grade) is important for defining the role of this technique in the diagnosis of 
breast cancer as well as the monitoring of neoadjuvant therapies.
This paper presents a practical clinical application of a quantitative pharmacokinetic model to study 
histologically confirmed and graded invasive human breast tumours. The hypothesis was that, given a 
documented difference in capillary permeability between benign and malignant breast tumours, a 
relationship between permeability-related DCE-MRI parameters and tumour aggressiveness persists 
within invasive breast carcinomas. In addition, it was hypothesised that pharmacokinetic parameters 
may demonstrate stronger correlation with prognostic factors than the more conventional black-box 
techniques, so a comparison was undertaken.
Significant correlations were found between pharmacokinetic and black-box parameters in 59 invasive 
breast carcinomas. However, statistically significant variation with tumour grade was only 
demonstrated in two permeability related pharmacokinetic parameters: kep (p<0.05) and K
trans
(p<0.05), using one-way analysis of variance. Parameters kep, and K
trans
 were significantly higher in 
Grade 3 tumours then in low grade tumours. None of the measured DCE-MRI parameters varied 
significantly between Grade 1 and Grade 2 tumours.
Measurement of kep and K
trans
 might therefore be used to monitor the effectiveness of neoadjuvant 
treatment of high grade invasive breast carcinomas, but is unlikely to demonstrate remission in low 
grade tumours.
Main Text
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Introduction
The blood circulation at the capillary level, or microcirculation, is determined by the metabolic 
activity of the tissue. In pathological processes (such as tumour genesis), the microcirculation becomes 
altered. There can be an increase in microvascular density resulting from the growth of new capillary 
networks (angiogenesis) as well as vasodilatation of existing vessels. With the relatively recent
Federal Drug Administration’s approval of drugs to target specifically angiogenesis, there is likely to 
be a requirement to monitor, non-invasively, the levels of angiogenic activity. Compartmental 
modelling using an MRI contrast agent gadopentetate dimeglumine (Gd-DTPA) and dynamic MRI 
acquisition offer the opportunity to investigate non-invasively and quantitatively the associated 
pharmacokinetics and hence the degree of angiogenic activity.
Gd-DTPA is an extracellular contrast agent which selectively alters the magnetic resonance signal 
intensity throughout its distribution volume which consists of plasma and extravascular extracellular 
fluid. Physiological parameters which determine tissue microcirculation have a direct influence on the
resulting local bulk tissue concentration of Gd-DTPA following intravenous administration. It is 
therefore possible to monitor the patho-physiological status of tissues by measuring the temporal 
variation of the MR signal and qualitative information can be obtained from viewing the changes in 
image contrast. More importantly, it is also possible to obtain quantitative information associated with 
angiogenesis by mathematical analysis of dynamic contrast-enhanced MRI (DCE-MRI). The 
investigation of angiogenesis using DCE-MRI techniques can be divided into two fundamentally 
different groups: the so-called black-box methods and the more complex pharmacokinetic methods.
In black-box methods, the effect of Gd-DTPA is quantified in terms of heuristic, descriptive 
parameters describing the degree and the time course of enhancement [1-5]. These black-box 
parameters include maximal enhancement (ME), initial rate of enhancement (IRE), time to peak (TTP) 
and wash out slope (WOS). Arguably, this method of analysis does not utilise optimally the available 
data as information from only selected parts of the dynamic curves are used. Furthermore, it is not 
possible to correlate findings obtained by different pulse sequences or to compare parameters 
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measured in different centres. In quantifying the extent of Gd-DTPA induced contrast enhancement, 
no presumptions are made about the underlying physical or physiological processes. Although these 
parameters are certainly related to the physiological parameters that govern tissue microcirculation, 
the form of this relationship is not considered.
In contrast, the pharmacokinetic methods for quantitative analysis of DCE-MRI provide a framework 
that can be used to link the physics of MRI signal acquisition and the underlying patho-physiology that 
governs Gd-DTPA kinetics [6-9]. Pharmacokinetic (or compartmental) modelling of Gd-DTPA 
kinetics allows quantification of physiologically relevant parameters such as the volume of the 
extravascular extracellular space and capillary permeability. The development of methods for the 
quantification of DCE-MRI based on pharmacokinetic modelling has largely centred on cancer 
applications and the assessment of blood brain barrier integrity. Within the context of pharmacokinetic 
modelling it is theoretically possible to separate the influence of physical and physiological parameters 
on the measured changes of signal intensity in DCE-MRI, thus enabling an assessment of 
physiological parameters that characterise pathological microcirculation.
Since its introduction into clinical practice by Heywang-Kobruner in 1986 [10], DCE-MRI has almost 
unequivocally demonstrated high sensitivity for detection of breast cancer [11]. The main limitation of 
DCE-MRI in the investigation of breast lesions lies in its low specificity and the majority of studies in 
this field centred on the design of methods for improving the distinction between malignant and 
benign breast lesions. The most basic criterion for the differentiation between benign and malignant 
lesions is the presence or absence of enhancement; this, however, yields a specificity of only 37%
[12]. Particularly problematic is the differentiation between benign fibroadenomas, ductal carcinoma 
in situ (DCIS), and some of the less angiogenesis-dependent types of cancer (such as invasive lobular 
carcinomas [13]). Improvement in DCE-MRI specificity in breast cancer (to 75-85%) can be achieved 
by its integration with other diagnostic findings and the formulation of precise inclusion criteria [13, 
14].
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The first reports of pharmacokinetic analysis of DCE-MRI were published in 1990 and 1991 by three 
independent European research groups in Copenhagen [7], Heidelberg [6] and London [9]. They
applied this technique to the assessment of the breakdown of the blood-brain barrier in multiple 
sclerosis [7, 9] and brain tumours [6, 7]. The potential of this approach for the assessment of 
microcirculatory properties of the tissues in a variety of other pathological states was quickly 
recognised. All subsequent models reported in the literature presented variations of these three 
principal models without radically changing the underlying methodology. Pharmacokinetic analysis of 
DCE-MRI was applied to the assessment of breast cancer [15-17], cervical cancer [18], colorectal 
cancer [19] and heart disease [20-22].
Although the three principal approaches rely on a common set of assumptions, they differ in the way 
the final formulation of the model-predicted tissue response curve is represented as a function of 
physiological parameters, and in the way these parameters are labelled and interpreted[23]. The key
differences in the practical implementation of these models are in the treatment of the temporal 
variation of the Gd-DTPA concentration in plasma, the choice of input function (mode of injection) 
and the measurement of native (pre-contrast) longitudinal relaxation time T1.
Although DCE-MRI was initially applied to the assessment of brain lesions, it has subsequently been 
used in the evaluation of a variety of tumours, with the research into Gd-DTPA pharmacokinetics in 
breast tumours being particularly prominent. Pharmacokinetic analysis was applied in several clinical 
studies of DCE-MRI in breast lesions where the primary aim of the quantitative analysis was the 
differentiation between benign and malignant tumours. Significantly higher permeability-related 
quantifiers of DCE-MRI were reported in invasive breast carcinomas than in benign lesions, although 
a variable degree of overlap between these groups of lesions was also noted in all published studies, 
regardless of the choice of the analysis method[24-30].
A comparison between black-box and pharmacokinetic analysis of DCE-MRI has been only 
sporadically reported the literature and the results of these comparisons are equivocal. Müller-
Schimpfle et al [31], for example, found that the application of pharmacokinetic modelling did not 
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result in the improvement in the discrimination between benign and malignant breast lesions when 
compared to black-box assessment. Hulka [27] and Mussurakis [24], on the other hand, reported that 
their pharmacokinetic parameters allowed a more specific classification of breast cancer lesions than 
black-box measurements (such as ER, ME and wash-out slope WOS). Whilst Müller-Schimpfle used 
Brix’s model for the extraction of pharmacokinetic parameters, Hulka applied Larsson’s method;
Mussurakis used both Brix and Tofts methods and found them to be equivalent. Temporal resolution 
of DCE-MRI in the Müller-Schimpfle study was low (one minute) whereas Hulka and Mussurakis 
used DCE-MRI sets acquired with a markedly higher temporal resolution of twelve and six seconds, 
respectively. The different conclusions reached in these studies regarding the comparative utility of 
pharmacokinetic and black-box methods are at least partly attributable to the differences in the DCE-
MRI acquisition protocols.
Only a few studies have attempted to directly correlate DCE-MRI findings with prognostic factors 
such as tumour grade and nodal status in clinical studies of breast cancer [32-36]. None of these 
studies included pharmacokinetic analysis of DCE-MRI. Their results appear to be inconclusive and
contradictory. Whilst Mussurakis [33] and Bone [35] found a significant correlation between DCE-
MRI and prognostic factors, Fischer [34] and Stomper [32] found no correlation between them. 
Different acquisition and sampling protocols have been employed in each of these studies, as well as 
different methods for quantitative analysis of DCE-MRI. Furthermore, there was a considerable 
variation in the number of patients/lesions studied, their histological mix, the method used for grading 
as well as the choice of prognostic factors that DCE-MRI was compared with (tumour grade, nodal 
status, DNA S-phase percentage as well as various immunohistochemical prognostic indicators). The 
temporal resolution of DCE-MRI acquisitions used in these studies ranged from 12 seconds [33], to 
seven minutes [35] with tissue coverage ranging from four targeted sagittal slices [33] to 64 transverse 
slices encompassing both breasts [35].
This paper presents a practical clinical application of a quantitative pharmacokinetic model [37] to 
study histologically confirmed and graded invasive human breast carcinomas and to investigate the 
capacity of pharmacokinetic measurements of permeability to reflect histological tumour grade and 
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node status. The hypothesis was that given a documented difference in capillary permeability between 
benign and malignant breast tumours, a relationship between permeability-related DCE-MRI
parameters and tumour aggressiveness persists within invasive breast carcinomas. In addition it was 
hypothesised that pharmacokinetic parameters may demonstrate a stronger correlation with prognostic 
factors than the more conventional black-box techniques so a comparison was undertaken.
Methods
Pharmacokinetic model
After intravenous injection, Gd-DTPA is rapidly distributed throughout the plasma volume and 
extravasated into the extracellular space. There is evidence that no metabolic trapping of Gd-DTPA 
occurs within the body and that it is completely eliminated in an unchanged form by renal excretion
[37]. Being a highly hydrophilic molecule, Gd-DTPA is unable to cross-cellular membranes. In an 
open two-compartment model of Gd-DTPA kinetics, the extravasation of Gd-DTPA from the central 
(plasma) compartment is represented by a transfer constant K
trans
. The back flux of Gd-DTPA from 
the extravascular extracellular compartment into the plasma compartment is represented by a transfer 
constant kep = K
trans
/ve, where ve denotes the fractional volume of the extracellular extravascular 
(leakage) space. Fractional elimination rate kel represents the clearance of Gd-DTPA from plasma. 
Pharmacokinetic parameters K
trans
 and kep therefore reflect the process of Gd-DTPA transfer across 
the capillary wall and are thus related to capillary permeability.
The pharmacokinetic modelling technique used in this paper combines the features of two earlier 
methods of Brix [6] and Tofts [8, 9]. This model [38] describes the temporal variation of contrast 
agent concentration in the tissue of interest Ct(t), as a function of two pharmacokinetic parameters: ve, 
and kep , as shown in equation 1.
  )(exp)1)((exp)(exp)1)exp(()( 21 tkkvtkku
T
aaD
vtC epep
W
el
W
elet  
(1)
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where: 
ve is the fractional volume of extravascular, extra cellular fluid (unit free fraction)
kep is the fractional transfer rate (expressed in min
-1
)
)/(1 Welep kkv 
vkku Welep )/(
W
elk  is the fractional elimination rate of 0.058 min
-1
 quoted by Weinmann et al [37]
a1 and a2 were determined from published data [37] and have the following values: a1 = 3.99 kg l
-1
, a2
= 4.78 kg l
-1
[9]
D is the injected dose of Gd-DTPA per kg body weight (D = 0.1 mmol kg
-1
)
T is the effective duration of the infusion
 = t for t T and  = T for t >T
For a spoiled gradient echo acquisition sequence, with repetition time TR, flip angle , the following 
approximation can be used at low concentrations Ct(t) to represent temporal variation of normalised 
signal intensity following intravenous injection of Gd-DTPA:
SI(t)/SI0 = 1 + a Ct(t) (2)
where: 
SI (t) is the signal intensity at time t
SI0 is the pre-injection signal intensity (i.e. t=0)
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a = [(exp( - TR / T1 ))/(1 – exp( - TR / T1 ))] TR α
Pre-contrast longitudinal relaxation time (T1) can be measured or an assumed fixed value can be used. 
In our method we used a published value of 876ms [39]
The pharmacokinetic parameter K
trans
(the transfer constant) is obtained from the product of kep and
ve (i.e. kep  ve). The three conventional pharmacokinetic parameters now extracted and presented are 
ve, kep and K
trans
.
Clinical implementation of the model
There were a number of criteria for the imaging protocol: (i) complete bi-lateral coverage of both 
breasts was required as one of the principal clinical objectives was the detection of possible 
multifocality, (ii) DCE-MRI was required to yield images of diagnostic quality, suitable for qualitative 
assessment by radiologists, (iii) the duration of the DCE-MRI acquisition was required to be short in 
order to minimise problems related to gross patient motion and patient discomfort.
All imaging was performed on a 1.5 T MRI scanner (Gyroscan ACS NT, Philips Medical Systems, 
Best, The Netherlands). The MR signal detection was performed with a standard bilateral breast coil. 
The selection of the imaging volume was performed following the acquisition of survey scans in three 
orthogonal directions ensuring complete coverage of both breasts.
A 2D multislice, T1-weighted spoiled gradient echo sequence was used (TR/TE/ = 213/4.6/90°, FOV 
= 300 x 300mm, 25 slices, 4mm slice thickness, 12 dynamic scans with temporal resolution of Delta T 
= 32.5 second acquisition intervals, 154  256 image matrix, reconstructed to 256  256 matrix). The 
acquisition protocol was based on that proposed by Kuhl et al [5] and the total imaging time was 390 
seconds. The patients were positioned prone with both breasts inside the breast coil. The imaging was
performed in the transverse plane, with the imaging volume encompassing both breasts in all three 
dimensions.
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A standard dose of 0.1 mmol per kilogram body weight of gadopentetate dimeglumine Gd-DTPA 
(Magnevist®, Schering, Berlin, Germany) was used. The Gd-DTPA injection was followed by a 10 ml
saline flush. The duration of the contrast administration was Tinf = (Delta T)/2 and effective duration 
of the infusion (T) which was used for the modelling was approximated by 2  Tinf. This 
approximation was based on the data reported by Andersen et al and Fritz-Hansen et al [20, 40] for 
short peripheral injections. Therefore, effective injection duration T was 32.5 seconds.
Figure 1 represents a pair of pre- and post-contrast images and a resulting subtraction image of the 
transverse slice cutting through the centre of the lesion. In routine clinical practice, the lesion is 
evaluated by placing a region of interest (ROI) on a subtraction image and displaying a SI/time curve 
on a MR console. The subtraction method is effective in delineating the extent of the lesion. However, 
these images are less suitable for the analysis of the internal architecture of the lesion and its 
relationship to the surrounding parenchyma.
To improve the visualisation of the lesions, parametric maps of the black-box parameters ME, IRE and 
WOS were computed on a voxel-by-voxel basis and displayed superimposed on grey-scale anatomical 
images (Figure 2). These parameters were extracted from dynamic curve for each voxel in the 3D 
array using algorithms implemented in C programming language. A three-point moving window 
algorithm encompassing temporal segments of 65 seconds was used for measurement of maximal 
enhancement over baseline (ME) and initial rate of enhancement (IRE). Parameter WOS (wash-out 
slope) was computed on a voxel-by-voxel basis by measuring the slope of the least-squares straight 
line through the fixed five-point window encompassing the last 130 seconds of the dynamic curves.
Three resulting colour coded images were interrogated simultaneously. No segmentation or motion 
correction was applied and a uniform colour-coding scheme was used in all studies. The computation 
of colour-coded parametric maps effectively condensed the information contained in the original 
DCE-MRI datasets. Following the visual inspection of parametric images, ROI selection was
performed using an image processing package Analyze
TM
 (Biomedical Imaging Resource; Mayo 
Foundation, Rochester, MN).
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The three pharmacokinetic parameters (K
trans
, ve, and kep) were calculated for each dynamic curve 
derived from a user-selected ROI. All processing was performed using a computer program for non-
linear least squares fitting employing the Levenberg-Marquardt algorithm adapted from Press [41]. 
The program was written in C programming language and run on a standard PC. The processing was 
performed in a single batch operation as no user input was required.
Patients
MRI examination of the breasts was performed in patients with breast lesions where conventional 
triple assessment (X-ray mammography, ultrasound and clinical examination) did not provide 
conclusive diagnosis and where further information about the extent of a known lesion and/or possible 
multifocality was being sought. The study was approved by the regional ethics review board and a 
written informed consent was obtained from every patient. From the total of 255 consecutive patients 
who underwent the MRI examination, surgery was subsequently carried out in 66 cases. A full 
pathology report, including tumour grade and lymph node status, was available for 53 patients (60 
lesions). Tumour grading was performed using the Nottingham Prognostic Index for primary breast 
cancer [42]. In one examination, quantitative analysis was not possible due to excessive patient 
motion.
Full DCE-MRI analysis was undertaken retrospectively in 59 lesions (in 52 patients). All patients were 
female with a median age of 55 (ranging from 32 to 80). The lesions were classified according to their 
histological grade into three groups. Twelve lesions were found to be Grade 1 tumours, twenty-nine
were Grade 2 and eighteen were Grade 3 tumours. Thirty lesions had negative node status and twenty-
nine were node positive. Forty-four lesions were classified as invasive ductal carcinomas not 
otherwise specified (NOS), eleven were invasive lobular carcinomas, two were invasive tubular 
carcinomas and two were invasive mucinous carcinomas. Thirty-four out of fifty-nine lesions had a 
significant in-situ (DCIS) component. Table 1 presents a summary of the pathology grading and 
lymph node status for the set of fifty-nine evaluated lesions.
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Following the inspection of parametric maps, the most representative (usually central) cross section 
was identified by a trained radiologist and a single circular 16-voxel ROI was placed close to the 
lesion rim and away from the necrotic, central areas, if present (Figure 3). Figure 4 illustrates dynamic 
curves extracted from two different lesions and the superimposed least squares lines obtained after 
non-linear fitting of the experimental data to the pharmacokinetic model. The corresponding 
pharmacokinetic and black-box parameters are listed in Table 2.
Statistical analysis
SPSS statistical software package (Version 13.0, SPSS, Chicago, IL) was used for statistical analysis. 
All statistical tests were performed at  = 0.05 confidence level.
Results
The technique worked robustly in this group of patients, adding only 5 minutes on to the investigation
time. Of all the tumours and patients studied the technique was only unsuccessful on one occasion
(due to excessive patient motion).
A summary of the black-box and pharmacokinetic parameters is presented in Tables 3 and 4
respectively. The mean values of measured parameters and their standard deviations are listed for each 
of the three subgroups. A pattern can be seen with a number of parameters (IRE, WOS, K
trans
, kep) 
with the parameter value changing in a consistent manner when compared to tumour grade. However, 
when a comparison is made of the pharmacokinetic and black-box parameters for the three different 
tumour groups using one way analysis of variance, statistically significant variation with tumour grade 
was only detected in K
trans
 (p<0.005) and kep (p<0.05), though the parameter WOS approaches 
significance (p=0.054).
The summary of results of the post-hoc analysis of the differences between individual groups of 
measurements is presented in Table 5. A Least Significant Difference correction for multiple 
comparisons was used. Whilst there were no significant differences between Grade 1 and Grade 2 
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tumours, Grade 3 tumours were significantly different from Grade 1 and Grade 2 tumours, with 
respect to kep and K
trans
.
The correlation of the DCE-MRI parameters with tumour grade and with each other is listed in Table 
6. There are significant correlations between tumour grade and WOS, kep and K
trans
 (p<0.01) and IRE
(p<0.05). K
trans
exhibited the highest degree of correlation with tumour grade (Spearman’s  = 0.473 
p <0.0005 ). The data for K
trans
 for each tumour group is plotted in Figure 5.
There was no significant association between DCE-MRI parameters and nodal status (Student’s t-test, 
p>0.05). Furthermore, groups with and without a significant DCIS component also did not vary 
significantly (Student’s t-test, p>0.05).
Discussion
In our study, the pharmacokinetic parameter K
trans
demonstrated a stronger relationship with tumour 
grade than the conventional black-box parameters, suggesting greater sensitivity to differences in 
microcirculation between different tumour grades.
The measurements obtained in this study are in good agreement with ve and K
trans
values in invasive 
breast carcinomas reported by Tofts et al (K
trans
of 0.1 – 1.2 min
-1
 and ve of 0.3 –0.8) [16], and den 
Boer et al (K
trans
of 1.05  0.75 min-1 and ve of 0.47  0.20 ) [28]. Whereas Tofts did not measure 
T10, den Boer included a pre-contrast measurement of T10 in the pharmacokinetic analysis. Our 
measurements of K
trans
 are somewhat higher than those obtained by Ikeda [30] (0.52  0.22 min-1) 
and Hulka et al [26, 27] (0.45  0.22 min-1) possibly as a result of different Cp(t) models. Both Ikeda 
and Hulka have modelled Cp(t) as a three-exponential function. None of these studies, however, 
included measurements of ve and K
trans
 in subgroups of invasive cancers, defined by histological 
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grade or nodal status. Furthermore, the proportion of high-grade tumours and tumours of different 
histological type will have influenced the mean values of K
trans
 and ve measured in all these studies.
Prior to undertaking this study a comparable measurement of permeability in different histological 
grades of human breast cancer had not, to our knowledge, been reported in the literature. Our 
measurements are in broad agreement with permeability-related measurements in invasive breast 
carcinomas in humans reported elsewhere in studies involving an unspecified mix of histological 
grades and nodal involvement [16, 28]. However Furman-Haran et al. have recently demonstrated the 
capacity of high resolution DCE-MRI to detect the differences in perfusion-related pharmacokinetic 
parameters between low-grade and high-grade invasive breast carcinomas [43].
Whilst it is not possible to trace all possible sources of discrepancy between the results presented in 
this study and other clinical studies where the relationship between tumour grade and black-box
quantifiers of DCE-MRI was investigated, one probable source of variability lies in the different 
acquisition sensitivity to underlying T1 changes. The most T1-sensitive acquisition sequence was used 
by Stomper et al [32, 36]. However, their studies included only a small number of subjects, and the 
imaging volume encompassed only five contiguous slices. Fischer et al [34] conducted a large study 
but employed a sub-optimal acquisition protocol, with respect to both temporal resolution (1.5 
minutes) and T1 sensitivity. In two studies where simple enhancement ratios displayed significant 
association with tumour grade [33, 35] and nodal status [33], T1 sensitivity was somewhat higher than 
that achieved by our acquisition protocol . Their superior T1 sensitivity, however, was associated with 
the concomitant loss of spatial coverage [33] and temporal resolution [35]. The present study provided 
a compromise between the conflicting requirements for high temporal and spatial resolution, tissue 
coverage and T1 sensitivity, all of which are important for determining the utility of breast cancer 
DCE-MRI examinations.
Pharmacokinetic analysis of DCE-MRI was put forward as a tool for non-invasive monitoring of the 
effects of neoadjuvant chemotherapy in breast cancer and the reduction in K
trans
 was associated with 
positive response to therapy [44, 45]. However, the reports presented in the literature to date are 
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contradictory. Whereas Manton et al report that pharmacokinetic parameters had no prognostic value 
[46], Padhani et al found that the change in K
trans
 was an accurate predictor of response [47].
In the present study, all lesions were evaluated by MRI before surgical excision without the 
administration of pre-surgical (neoadjuvant) chemotherapy. Successful neoadjuvant chemotherapy 
could be viewed as an effective downgrading of the tumour (e.g. from Grade 3 to Grade 2, or from
Grade 2 to Grade 1). Therefore, our measurements of DCE-MRI pharmacokinetic parameters in 
graded primary breast carcinomas may offer an insight into the mechanisms involved in the 
monitoring of the effects of neoadjuvant chemotherapy by pharmacokinetic analysis of DCE-MRI.
There was a high degree of correlation between black-box and pharmacokinetic factors (Table 6). 
However, pharmacokietic parameters Ktrans and kep exhibited the highest degree of correlation with 
tumour grade.
Furthermore, our results indicate that permeability related pharmacokinetic parameters K
trans
and kep
vary significantly between Grade 3 and Grade 2 tumours, whereas there is no significant difference 
between Grade 2 and Grade 1 tumours (Table 2). This suggests that pharmacological downgrading of 
Grade 3 tumours can be detected by measuring the changes in K
trans
 and kep, and that further 
remission (from Grade 2 to Grade 1) will not result in significant change in K
trans
 and kep.
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1Table 1: Summary of histological status of breast cancer lesions
Node positive Node negative Total
Grade 1 10 2 12
Grade 2 11 18 29
Grade 3 9 9 18
Total 30 29 59
Table 1
1Table 2. Pharmacokinetic and “black-box” measured in two different lesions (with DCE-MRI curves 
presented in Figure 4.)
ROI1
(Grade 1 node negative)
ROI2
(Grade 3 node positive)
ME 1.68 2.39
WOS [min
-1
] 0.020 -0.008
IRE [min-1] 0.690 1.833
ve 0.275 0.535
K
trans
 [min-1] 0.194 0.815
kep [min
-1] 0.706 1.523
Table 2
1Table 3. Summary of black-box variables 
ME IRE [min
-1
] WOS [min
-1
]
Grade 1 (n =12 ) 2.04 (0.33) 1.32 (0.44) 0.017 (0.066)
Grade 2 (n =29) 2.20 (0.36) 1.50 (0.6) -0.007 (0.056)
Grade 3 (n =18) 2.26 (0.29) 1.75 (0.48) -0.035 (0.056)
Table 3
1Table 4. Summary of pharmacokinetic variables
ve K
trans
 [min
-1
] kep [min
-1
]
Grade 1 (n =12 ) 0.39 (0.13) 0.61 (0.28) 1.62 (0.82)
Grade 2 (n =29) 0.46 (0.14) 0.91 (0.73) 2.04 (1.60)
Grade 3 (n =18) 0.46 (0.11) 1.41 (0.69) 3.17 (1.62)
Table 4
1Table 5. Significance of the difference of pharmacokinetic variables K
trans
and kep between tumour grades 
Grade 1 vs Grade 2 Grade 1 vs Grade 3 Grade 2 vs Grade 3
K
trans n.s. p<0.005 p<0.05
kep n.s. p<0.01 p<0.05
Table 5
1Table 6: Correlations between DCE-MRI parameters and tumour grade (all correlation coefficients are 
Pearson’s , apart from those related to tumour grade, where Spearman’s  is listed instead). 
ME IRE WOS ve K
trans
kep
Tumour grade 0.228 0.274* -0.334** 0.182 0.473** 0.420**
ME 1 0.817** -0.013 0.981** 0.377** 0.027
IRE 1 -0.289* 0.747** 0.550** 0.299*
WOS 1 0.117 -0.563** -0.626**
ve 1 0.263* -0.095
K
trans 1 0.910**
kep 1
* p<0.05
** p<0.01
Table 6
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Figures
Figure 1: Pre-contrast, post-contrast and subtraction image derived form a DCE-MRI dataset
Figure 2: Parametric maps of the variables ME (left), IRE (middle) and WOS (right) corresponding to 
the images presented in Figure 1
Figure 3: The ROI illustrated is superimposed onto a colour map of variable IRE. However, ROI 
selection was based on simultaneous inspection of all three parametric maps in Figure 2
Figure 4: Examples of dynamic curves from 2 ROIs derived form a Grade 1 lesion (left) and a Grade 3 
lesion (right). DCE-MRI parameters are listed in Table 2
Figure 5. K
trans
 values for all tumours in the three histological groups
* Figure legends
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Figure 5
